How Long Does a Herpes Flare-Up Last? First vs. Recurrent

A first herpes outbreak typically lasts two to three weeks and tends to be the most severe episode a person will ever experience. Recurrent flare-ups, by contrast, are shorter and milder, with most resolving in roughly five to ten days. But those ballpark numbers only tell part of the story, because duration varies depending on the virus type involved, whether you take antiviral medication, how many years have passed since your first infection, and how your immune system is functioning.

The First Episode Is the Longest

When herpes simplex virus infects someone for the first time, the immune system has never encountered it before. That initial lack of antibodies means the virus replicates with relatively little resistance, producing a first outbreak that is typically more widespread and more painful than anything that follows. Blisters or sores can appear in clusters, sometimes accompanied by flu-like symptoms such as fever, body aches, and swollen lymph nodes. Without antiviral treatment, the sores from a primary episode usually take two to three weeks to crust over and heal completely.

Viral shedding during this initial period is also at its highest level. In the first year after infection, people with genital HSV-2 shed the virus on roughly a third of all days sampled, compared to about a fifth of days for those one to nine years out, and about one in six days for those a decade or more past their first episode.¹ That steady decline in shedding frequency over the years helps explain why outbreaks generally become less common and less intense as time goes on.

Recurrent Outbreaks Are Shorter and Milder

Once the immune system has built up antibodies and T-cell responses to herpes simplex, it can contain reactivations much more quickly. A recurrent genital herpes flare-up typically lasts around five days at the median when visible lesions are present, though the range stretches from about three to nine days depending on the individual.² The sores are usually fewer, smaller, and confined to a more localized area than during the first episode. Many people notice a pattern of tingling or burning in the same spot before sores appear, a warning phase often called the prodrome, which can last a few hours to a day or two before blisters break through.

Not every reactivation produces visible sores. Subclinical shedding episodes, where the virus reaches the skin surface without causing symptoms you can see or feel, tend to be even briefer, averaging around one and a half days.³ These invisible episodes are relevant because the virus can still be transmitted during them, but they do not add to the physical discomfort of a recognized flare-up.

HSV-1 vs. HSV-2 in the Genital Area

The two types of herpes simplex virus are not interchangeable when it comes to genital outbreaks. HSV-2 is the traditional cause of genital herpes, but HSV-1, the type more commonly associated with cold sores, is an increasingly common cause of genital infections, particularly through oral-to-genital contact. The distinction matters for duration and recurrence rates.

HSV-2 genital infections recur more frequently and individual outbreaks tend to last longer than genital HSV-1 infections.⁴ The reason appears to lie in how much latent virus sets up camp in the nerve ganglia serving the genital region. HSV-2 stores more copies of its genetic material in the lumbosacral ganglia than HSV-1 does, giving it a larger reservoir from which to reactivate. In practical terms, if you have genital HSV-1, you can expect fewer and shorter recurrences over your lifetime compared to someone with genital HSV-2. Many people with genital HSV-1 have only one or two recurrences ever, while those with HSV-2 may have several per year, especially in the early years.

How Antiviral Medication Shortens a Flare-Up

Antiviral drugs are the most effective tool for cutting an outbreak short. The three main antivirals used for herpes are acyclovir, valacyclovir, and famciclovir. They all work by the same basic mechanism: blocking the enzyme the virus needs to copy its DNA, which slows viral replication and gives the immune system a head start in clearing the episode.

Timing is everything. For episodic treatment of a recurrent outbreak, starting an antiviral at the first sign of tingling or redness makes a meaningful difference. In a randomized trial, a single day of famciclovir treatment shortened healing time and reduced pain by about two days compared to placebo, and it prevented a full outbreak from developing in roughly one out of four patients who took it early.⁵ Similarly, a one-day course of high-dose valacyclovir reduced cold sore episodes by about a day on average compared to placebo, with faster lesion healing and shorter duration of pain.⁶

If you wait until blisters have already formed and broken open, antivirals still help, but the benefit shrinks. The drugs cannot repair tissue damage that has already occurred. They are shutting down the viral factory, not healing the wound after the fact. So the general rule is: the earlier you start, the shorter the outbreak.

Suppressive Therapy and Long-Term Recurrence Patterns

For people who get frequent recurrences, taking a low dose of an antiviral every day can reduce both how often outbreaks happen and how much virus is shed between them. In a five-year study of daily acyclovir, the average number of recurrences per year dropped from 1.7 during the first year to 0.8 by the fifth year. More than one in five patients remained completely recurrence-free over the entire five-year period.⁷ When breakthroughs did occur, the individual outbreaks were not shorter than they would have been otherwise. The benefit of suppressive therapy is mainly in reducing how often flare-ups happen, not in making each one heal faster.

Suppressive therapy does reduce viral shedding, which lowers the risk of transmitting the virus to a partner. However, breakthrough shedding still occurs at all antiviral doses. Even at higher-than-standard doses, the virus still reactivates periodically, though less frequently.⁸ Suppressive therapy is a management tool, not a cure, and it works best when combined with other precautions like condom use for people concerned about transmission.

Topical Treatments for Oral Herpes

For cold sores on or around the lips, docosanol (sold over the counter as Abreva) is the most widely available topical treatment. It works differently from prescription antivirals: rather than targeting viral replication directly, it interferes with the virus’s ability to fuse with healthy skin cells. The effect on duration is real but modest. In a large trial, docosanol cream reduced the median time to healing by about 18 hours compared to placebo.⁹

As with antivirals, timing is the key variable. When docosanol was applied early, at the first prodromal tingling or redness stage, it shortened mean healing time by roughly three days compared to late application or placebo.¹⁰ Applied after blisters have already formed, the benefit shrinks considerably. The consistent theme across both prescription and over-the-counter treatments is that early intervention makes the biggest difference in how long a flare-up sticks around.

What Triggers a Recurrence

Between outbreaks, herpes simplex virus sits dormant in nerve ganglia. The immune system keeps it in check through a chronic, low-level immune patrol. Immune cells, particularly T cells, cluster around the ganglia and maintain a kind of ongoing surveillance that suppresses viral reactivation.¹¹ When that immune balance gets disrupted, the virus can slip past the defenses and travel back down the nerve to the skin, producing a new flare-up.

Several triggers are commonly cited by people with herpes, though the scientific evidence supporting each one varies in strength:

Ultraviolet light: UV-B exposure is one of the most reliably demonstrated triggers, particularly for oral herpes. Lab and clinical studies confirm that UV-B light is a potent stimulus for reactivating latent HSV.¹² Sunburn on the lips or genital area from strong sun exposure is a well-recognized trigger.
Illness or fever: Anything that temporarily diverts immune resources, such as a cold, flu, or other infection, can give the virus an opening to reactivate. This is why cold sores are colloquially called “fever blisters.”
Physical trauma or friction: Local irritation to the area where the virus resides can provoke a flare-up. For genital herpes, this sometimes includes vigorous sexual activity or skin procedures.
Hormonal changes: Some women report outbreaks timed to their menstrual cycle, though controlled studies have produced mixed results on whether menstruation is a consistent independent trigger.

The Complicated Relationship Between Stress and Outbreaks

Ask almost anyone with herpes whether stress triggers their outbreaks and they will likely say yes. The scientific picture is more nuanced than the popular belief, though it does lean in that direction for certain kinds of stress.

The clearest evidence comes from a study that tracked women with genital HSV-2 over time, measuring daily stress, anxiety, and depression levels alongside swab-confirmed shedding and lesion data. Average stress over the study period was linked to about a 10% increase in the frequency of lesion episodes. High stress levels five days before an outbreak were associated with at least three times the rate of lesion onset compared to low stress levels. High anxiety and depression showed even stronger associations on certain days before lesion onset.¹³ Interestingly, stress levels were not associated with viral shedding itself, only with the appearance of visible lesions. That distinction suggests stress may affect the inflammatory response at the skin surface rather than directly provoking the virus to leave the nerve ganglia.

Another study found that persistent stress, defined as stressors lasting more than a week, predicted herpes recurrence in the following week. But short-lived stressors, momentary anger, and passing anxiety did not.¹⁴ A bad day at work is probably not going to cause an outbreak. Ongoing financial strain, relationship conflict, or chronic job stress is a different story. Animal research supports this too: disrupting the social hierarchy in mouse colonies, which creates sustained social stress, reactivated latent HSV-1 in more than 40% of infected animals.¹⁵

Not all studies agree, however. A prospective study of patients with herpes simplex eye infections found no significant association between self-reported psychological stress and recurrence risk, and no link between sunlight exposure, menstrual periods, or contact lens wear and flare-ups of ocular herpes.¹⁶ The discrepancy likely reflects differences in the anatomical site involved, the method of measuring stress, and study design. Overall, the weight of evidence suggests that chronic, grinding stress raises the risk of recurrence, while acute, short-lived stress plays a smaller or negligible role.

When Outbreaks Do Not Follow the Usual Timeline

The durations discussed above assume a reasonably healthy immune system. For people who are immunocompromised, whether from HIV, organ transplant medications, chemotherapy, or other causes, herpes flare-ups can behave very differently. Outbreaks may last weeks or months instead of days, sores can grow unusually large, and the virus may not respond to standard antiviral doses.

In people with HIV, HSV-2 reactivates more frequently and can produce atypical presentations including hypertrophic or tumor-like genital lesions that do not resemble typical herpes at all.¹⁷ These unusual lesions have been documented even in HIV-positive patients whose immune systems had substantially recovered on antiretroviral therapy. In one reported case, a large vegetative perianal lesion developed over a full year in an HIV-positive patient before it was identified as herpes.¹⁸

These chronic, atypical presentations have also been described in rare instances outside the HIV-positive population, including in patients on immunosuppressive medications for autoimmune conditions.¹⁹ When a genital sore persists for weeks without healing or looks unusual, it is worth mentioning to a healthcare provider even if a herpes diagnosis was not initially suspected, since the clinical picture in immunocompromised individuals can mimic other conditions.

Why Outbreaks Tend to Improve Over the Years

One of the most reassuring aspects of herpes is that the natural history bends toward improvement. For most people, the first year after infection is the worst in terms of outbreak frequency, duration, and viral shedding. As the years pass, the immune system’s ability to control the virus improves. Shedding frequency drops substantially: from about a third of sampled days in the first year to roughly one in six days a decade later.¹ The amount of virus shed on any given day also decreases modestly over time.

Many people find that after the first few years, recurrences become infrequent enough to barely register in their daily lives, particularly those with genital HSV-1. For those with HSV-2 who still experience bothersome recurrences after the first couple of years, suppressive therapy remains an option, and it tends to become less necessary as the natural decline in outbreak frequency continues. Some people who started suppressive therapy early choose to take periodic breaks to see whether their outbreak frequency has dropped to a manageable level without medication. There is no established rule for when to try stopping, but five or more years after initial infection is a reasonable point to reassess with a doctor.

Subclinical Shedding and What It Means for Transmission

The concept that matters most for people concerned about passing herpes to a partner is that viral shedding does not require a visible outbreak. On days when the virus reaches the skin surface without producing sores, shedding episodes are brief, typically around one to two days, but they are frequent enough to be the leading route of transmission.³ Many people who transmit herpes to a partner do so during one of these invisible episodes rather than during a recognized outbreak.

This is why avoiding sex only during visible flare-ups, while helpful, is not a complete prevention strategy. Combining abstinence during outbreaks with daily suppressive antivirals and consistent condom use gives the lowest transmission risk. Even so, the risk is never zero. Understanding that shedding happens on days when everything looks and feels normal can reduce the guilt and confusion that often accompanies a new partner’s diagnosis, since it means transmission does not necessarily reflect carelessness or deception on anyone’s part.

Shedding episodes with visible lesions last longer, at a median of about five days, while subclinical episodes are much shorter.² The practical takeaway is that a visible outbreak is a high-transmission window, but the absence of sores does not guarantee zero risk.

1
Oxford Academic (The Journal of Infectious Diseases). Persistent Genital Herpes Simplex Virus-2 Shedding Years Following the First Clinical Episode
2
PubMed Central. Genital Shedding of Herpes Simplex Virus Among Symptomatic and Asymptomatic Persons with HSV-2 Infection – Section: Shedding Episode Frequency and Duration
3
PubMed. Virologic characteristics of subclinical and symptomatic genital herpes infections
4
PubMed Central. The quantity of latent viral DNA correlates with the relative rates at which herpes simplex virus types 1 and 2 cause recurrent genital herpes outbreaks
5
PubMed Central. Single-day therapy: an expert opinion on a recent development for the episodic treatment of recurrent genital herpes
6
PubMed Central. High-dose, short-duration, early valacyclovir therapy for episodic treatment of cold sores: results of two randomized, placebo-controlled, multicenter studies
7
Archives of Dermatology. Long-term Suppression of Recurrent Genital Herpes With Acyclovir: A 5-Year Benchmark
8
The Lancet. Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials
9
PubMed. Clinical efficacy of topical docosanol 10% cream for herpes simplex labialis: A multicenter, randomized, placebo-controlled trial
10
Acta Dermato-Venereologica. n-Docosanol 10% cream in the treatment of recurrent herpes labialis: a randomised, double-blind, placebo-controlled study
11
PubMed Central. Latent herpesvirus infection in human trigeminal ganglia causes chronic immune response
12
PubMed. UV light-induced reactivation of herpes simplex virus type 2 and prevention by acyclovir
13
PubMed Central. The Effects of Daily Distress and Personality on Genital HSV Shedding and Lesions in a Randomized, Double-blind, Placebo-Controlled, Crossover Trial of Acyclovir in HSV-2 Seropositive Women
14
JAMA Internal Medicine. Persistent Stress as a Predictor of Genital Herpes Recurrence
15
PubMed Central. Social stress and the reactivation of latent herpes simplex virus type 1
16
PubMed. Psychological stress and other potential triggers for recurrences of herpes simplex virus eye infections
17
PubMed Central. Progressive hypertrophic genital herpes in an HIV-infected woman despite immune recovery on antiretroviral therapy
18
PubMed. Atypical presentation of herpes simplex (chronic hypertrophic herpes) in a patient with HIV infection
19
International Journal of Women’s Dermatology. Vulvar pseudotumoral acyclovir-resistant herpes in an HIV-negative, non-immunosuppressed patient: A therapeutic challenge